MPR Launches Global CRO Strategic Alliance
To expand the scale and scope of its operations, MPR announced the launch of a development group embracing its global strategic alliance with additional four CRO’s in India, South America, Russia, and Central Europe.
This move expands the company’s capabilities in early phase clinical research in India and Argentina, central lab capabilities in Russia, and increases the number of countries to support clinical research with additional five major countries in South America and Eastern Europe.
The Strategic Alliance initiative intends to combine the resources of the participating companies leading to potentially merging some or all of these companies’ assets. The terms of the alliances contracts are flexible. This initiative will optimize delivery, increase efficiency and reduce costs of services provided by the Company.
The CRO business of the Company will be rebranded as MPR Development Group. Plans to spin off CRO business under this name and to set up an independent company structure are contemplated by the Board of Directors of the Company in coordination with few professional investors.
The four CRO’s joining the MPR CRO Alliance are: ACCELL Clinical Research (Russia and Ukraine), Cromos Pharma (USA based CEE CRO), Fortis Clinical Research (India), and Research Development RA. S.A. (South America),
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
